Trial | NCT01049347  Report issue

Title

Amitriptyline and Paroxetine Treatment of Major Depression
Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    127
Activation of the hypothalamus-pituitary-adrenal system is monitored using saliva cortisol sampling during the antidepressant treatment with amitriptyline and paroxetine in moderately to severely depressed patients. Additionally, serum and plasma are sampled during the 5-week study period in order to study endocrine and metabolic parameters.
Study Started
Oct 31
1997
Primary Completion
May 31
2000
Study Completion
May 31
2000
Last Update
Jan 14
2010
Estimate

Drug amitriptyline

150 mg oral, daily, single evening dose, 35 days

Drug paroxetine

40 mg oral, single dose, morning, 35 days

amitriptyline Active Comparator

paroxetine Active Comparator

Criteria 

Inclusion Criteria:

age: above 18
depression according DSM-IV

Exclusion Criteria:

bipolar disorder
substance dependency
No Results Posted